The estimated Net Worth of Ramy Farid is at least $16.2 Million dollars as of 4 January 2023. Dr Farid owns over 66,886 units of Schrodinger stock worth over $5,172,124 and over the last 5 years he sold SDGR stock worth over $9,979,800. In addition, he makes $1,010,921 as CEO and Pres & Director at Schrodinger.
Dr has made over 3 trades of the Schrodinger stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 66,886 units of SDGR stock worth $80,263 on 4 January 2023.
The largest trade he's ever made was selling 130,000 units of Schrodinger stock on 12 August 2020 worth over $8,915,400. On average, Dr trades about 24,098 units every 97 days since 2020. As of 4 January 2023 he still owns at least 251,318 units of Schrodinger stock.
You can see the complete history of Dr Farid stock trades at the bottom of the page.
Dr. Ramy Farid Ph.D. is the CEO, Pres & Director at Schrodinger.
As the CEO and Pres & Director of Schrodinger, the total compensation of Dr D at Schrodinger is $1,010,921. There are no executives at Schrodinger getting paid more.
Dr D is 57, he's been the CEO and Pres & Director of Schrodinger since . There are 6 older and 15 younger executives at Schrodinger. The oldest executive at Schrodinger, Inc. is Dr. Richard A. Friesner, 68, who is the Co-Founder, Scientific Advisory Chairman and Director.
Ramy's mailing address filed with the SEC is C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158.
Over the last 5 years, insiders at Schrodinger have traded over $1,009,056,149 worth of Schrodinger stock and bought 838,235 units worth $14,249,995 . The most active insiders traders include & Melinda Gates Foundation ..., David E Schrodinger Equity ..., and Michael Lynton. On average, Schrodinger executives and independent directors trade stock every 10 days with the average trade being worth of $2,459,207. The most recent stock trade was executed by Kenneth Patrick Lorton on 6 March 2024, trading 5,574 units of SDGR stock currently worth $24,191.
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Schrodinger executives and other stock owners filed with the SEC include: